Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Korro Bio (KRRO) Short term Debt (2021 - 2023)

Korro Bio's Short term Debt history spans 3 years, with the latest figure at $11.7 million for Q1 2023.

  • For the quarter ending Q1 2023, Short term Debt rose 250.05% year-over-year to $11.7 million, compared with a TTM value of $11.7 million through Mar 2023, up 250.05%, and an annual FY2022 reading of $10.0 million, up 1100.48% over the prior year.
  • Short term Debt for Q1 2023 was $11.7 million at Korro Bio, up from $10.0 million in the prior quarter.
  • The five-year high for Short term Debt was $11.7 million in Q1 2023, with the low at $833000.0 in Q4 2021.
  • Average Short term Debt over 3 years is $6.7 million, with a median of $7.1 million recorded in 2022.
  • Year-over-year, Short term Debt soared 1100.48% in 2022 and then skyrocketed 250.05% in 2023.
  • Tracing KRRO's Short term Debt over 3 years: stood at $833000.0 in 2021, then soared by 1100.48% to $10.0 million in 2022, then grew by 16.67% to $11.7 million in 2023.
  • Per Business Quant, the three most recent readings for KRRO's Short term Debt are $11.7 million (Q1 2023), $10.0 million (Q4 2022), and $8.3 million (Q3 2022).